PYLARIFY has achieved a significant milestone in nuclear medicine, becoming the first radiodiagnostic agent to surpass $1 billion in annual net sales. The diagnostic imaging agent generated $1 billion in 2024 sales, reflecting 24.3% year-over-year growth and establishing a new commercial benchmark for the radiodiagnostic category.
The broader PSMA-targeted therapeutic market continues to demonstrate robust commercial momentum, with PLUVICTO, a radioligand therapeutic agent, reporting $1.392 billion in 2024 sales alongside 42% growth. This strong performance by both diagnostic and therapeutic agents underscores the clinical validation and market acceptance of PSMA-targeted approaches in prostate cancer management.
The competitive landscape for PSMA-targeted technologies remains dynamic, with multiple radioligand candidates in development across pharmaceutical pipelines. Industry analysts expect continued expansion of this market segment as additional therapies advance through clinical development and regulatory approval processes, further solidifying PSMA-targeted approaches as a cornerstone of modern prostate cancer care.